PHF19 inhibition as a therapeutic target in multiple myeloma

Curr Res Transl Med. 2021 Jul;69(3):103290. doi: 10.1016/j.retram.2021.103290. Epub 2021 Apr 22.


Epigenetic deregulation is increasingly recognized as a contributing pathological factor in multiple myeloma (MM). In particular tri-methylation of H3 lysine 27 (H3K27me3), which is catalyzed by PHD finger protein 19 (PHF19), a subunit of the Polycomb Repressive Complex 2 (PRC2), has recently shown to be a crucial mediator of MM tumorigenicity. Overexpression of PHF19 in MM has been associated with worse clinical outcome. Yet, while there is mounting evidence that PHF19 overexpression plays a crucial role in MM carcinogenesis downstream mechanisms remain to be elucidated. In the current study we use a functional knock down (KD) of PHF19 to investigate the biological role of PHF19 and show that PHF19KD leads to decreased tumor growth in vitro and in vivo. Expression of major cancer players such as bcl2, myc and EGR1 were decreased upon PHF19KD further underscoring the role of PHF19 in MM biology. Additionally, our results highlighted the prognostic impact of PHF19 overexpression, which was significantly associated with worse survival. Overall, our study underscores the premise that targeting the PHF19-PRC2 complex would open up avenues for novel MM therapies.

MeSH terms

  • Cell Proliferation
  • DNA-Binding Proteins
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • Polycomb Repressive Complex 2
  • Transcription Factors / genetics


  • DNA-Binding Proteins
  • PHF19 protein, human
  • Transcription Factors
  • Polycomb Repressive Complex 2